At the Drug Delivery to the Lungs (DDL) Conference, 6 - 8th December 2017, Edinburgh, UK, discuss your development challenges for pulmonary and nasal drug delivery
The Drug Delivery to the Lungs conference (DDL) is Europe’s premier conference and industry exhibition dedicated to pulmonary and nasal drug delivery. The conference will cover some of the major issues for these product types including new and repurposed drugs, novel formulations and drug combinations, generic inhalers and innovative inhaled treatments based on advances in clinical science and respiratory medicine. Novel inhaler technology, new devices and performance enhancements and novel methods for aerosol measurement and characterisation will also also be discussed.
We are delighted to announce that we are platinum sponsors for the 28th DDL Conference. During DDL, our team of experts will be available to discuss your inhalation product development, inhalation product testing, formulation development or stability testing challenges. Contact our team now to arrange a meeting during the conference
Delivery of drugs to the lungs offers a topical route to treat respiratory disease which is often quicker, more efficacious and requiring less API than if orally or parenterally administered. Delivery to the respiratory tract can also offer a quick and direct route to systemic drug delivery. The range of molecules being considered for delivery by inhalation has recently expanded to include novel drugs for lung infection, combination therapies, biopharmaceuticals and candidates for systemic delivery. For each new inhaled drug development, an excellent understanding of the API, formulation, stability and dose delivery characteristics is essential to ensure a safe and effective medicine.
WHITEPAPER DOWNLOAD: Formulation of Biologics for Inhaled and Nasal Delivery
WEBINAR RECORDING: Stability Programs for Orally Inhaled or Nasal Drug Products
WEBINAR RECORDING: The Fundamentals of Inhaled Product Testing
Learn More about the DDL 2 Conference
The Drug Delivery to the Lungs conference (DDL) is Europe’s premier conference and industry exhibition which is dedicated to pulmonary and nasal drug delivery. DDL provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation. DDL2017 will have five themed sessions that include: Inhaled Therapy in Special Populations, Emerging Therapeutics and Novel Respiratory Medicines, Inhalation Devices and Aerosol Science and Modelling and Simulations in Inhalation Science.
Need help or have a question?